Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study is a research paper published in Cancer (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: UG1 CA189819
NCI NIH HHS
Grant: UG1 CA233327
NCI NIH HHS
Grant: UG1 CA233339
NCI NIH HHS
Grant: U10 CA180882
NCI NIH HHS
Grant: U10CA180821
NCI NIH HHS
Grant: UG1 CA189824
NCI NIH HHS
Grant: UG1 CA233323
National Cancer Institute
Grant: UG1CA189850
National Cancer Institute
Grant: UG1CA233191
NCI NIH HHS
Grant: R50 CA275927
NCI NIH HHS
Grant: U24 CA196171
NCI NIH HHS
Grant: UG1CA233180
NCI NIH HHS
Grant: UG1 CA233253
NCI NIH HHS
Grant: UG1CA233331
NCI NIH HHS
Grant: UG1 CA239758
NCI NIH HHS
Grant: UG1 CA233373
Bayer
Sanofi Genzyme
FWCI
3.30
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals